Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique Le dépôt du dossier réglementaire pour l’initiation de l’essai clinique de Phase 2a évaluant son candidat...
-
PannTheraPi files Phase 2a trial for epilepsy drug PTI5803, secures EU patent, and appoints Sophie Binay as GM & CSO.
-
Dr. Joshua Hare, CSO and Exec Chairman interviewed on NPR's BioTech Nation, discussing potential breakthrough stem cell therapy for HLHS.
-
Scenic Biotech taps Dr. Bürli as Chief Scientific Officer to lead development of innovative drug candidate pipeline fueled by the company’s Cell-Seq platform. Amsterdam, the Netherlands, September...
-
• Stefan Ries joins as CSO, bringing more than two decades of drug development experience in the pharmaceutical industry complemented by a background in venture capital • Elena Ardini joins as...
-
OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D.,...
-
Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an...
-
SAN FRANCISCO and TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Global cybersecurity venture capital firm, YL Ventures, today announced the appointment of Andy Ellis, formerly an Operating...
-
Report examines the marketing & security relationship & how marketing leaders can preserve brand reputation amid rising data privacy & security concerns.
-
Boston, June 17, 2024 (GLOBE NEWSWIRE) -- CSO, the leading source for breaking news, analysis, and research on security and risk management, has announced the winners of the 2024 CSO Awards and...